hVIVO plc (LON:HVO - Get Free Report) shares dropped 46.3% on Saturday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares were traded during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Analyst Ratings Changes
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research report on Friday.
View Our Latest Stock Analysis on HVO
hVIVO Stock Up 23.0%
The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a market capitalization of £75.71 million, a P/E ratio of 4.41 and a beta of 0.97. The firm has a 50-day moving average price of GBX 16.16 and a two-hundred day moving average price of GBX 18.04.
hVIVO (LON:HVO - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Equities research analysts anticipate that hVIVO plc will post 1.5492958 EPS for the current fiscal year.
Insider Activity at hVIVO
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). 14.03% of the stock is currently owned by corporate insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Recommended Stories
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
